PURPOSE OF REVIEW: Given the recent availability of antiretroviral therapy (ART) in resource-limited settings and the significant burden exacted by Kaposi's sarcoma in these areas, we reviewed data regarding the impact of ART on Kaposi's sarcoma incidence. We summarized the sizeable literature in resource-rich settings as well as emerging data from resource-limited regions. Importantly, we delineated ways impact can be defined, including individual patient-level effectiveness; population-level effectiveness; change in population-level incidence; and residual risk of Kaposi's sarcoma. RECENT FINDINGS: In resource-rich settings, there are now ample data demonstrating beneficial individual patient-level and population-level effects of ART on Kaposi's sarcoma incidence. There is, however, considerable variability between studies and important methodologic shortcomings. Data from resource-limited settings are much more limited; although they preliminarily indicate individual patient-level effectiveness, they do not yet provide insight on population-level effects. SUMMARY: ART has had a substantial impact on Kaposi's sarcoma incidence in resource-rich settings, but more attention is needed on validly quantifying this effect in order to determine whether additional interventions are needed. Emerging data from resource-limited regions also suggest beneficial impact of ART on Kaposi's sarcoma incidence, but - given the scope of Kaposi's sarcoma in these settings - more data are needed to understand the breadth and magnitude of the effect.
PURPOSE OF REVIEW: Given the recent availability of antiretroviral therapy (ART) in resource-limited settings and the significant burden exacted by Kaposi's sarcoma in these areas, we reviewed data regarding the impact of ART on Kaposi's sarcoma incidence. We summarized the sizeable literature in resource-rich settings as well as emerging data from resource-limited regions. Importantly, we delineated ways impact can be defined, including individual patient-level effectiveness; population-level effectiveness; change in population-level incidence; and residual risk of Kaposi's sarcoma. RECENT FINDINGS: In resource-rich settings, there are now ample data demonstrating beneficial individual patient-level and population-level effects of ART on Kaposi's sarcoma incidence. There is, however, considerable variability between studies and important methodologic shortcomings. Data from resource-limited settings are much more limited; although they preliminarily indicate individual patient-level effectiveness, they do not yet provide insight on population-level effects. SUMMARY:ART has had a substantial impact on Kaposi's sarcoma incidence in resource-rich settings, but more attention is needed on validly quantifying this effect in order to determine whether additional interventions are needed. Emerging data from resource-limited regions also suggest beneficial impact of ART on Kaposi's sarcoma incidence, but - given the scope of Kaposi's sarcoma in these settings - more data are needed to understand the breadth and magnitude of the effect.
Authors: Mary-Ann Davies; Andrew Boulle; Brian Eley; Harry Moultrie; Karl Technau; Helena Rabie; Gilles van Cutsem; Janet Giddy; Robin Wood; Matthias Egger; Olivia Keiser Journal: Trop Med Int Health Date: 2011-08-11 Impact factor: 2.622
Authors: Sharon Pipkin; Susan Scheer; Ijeoma Okeigwe; Sandra Schwarcz; David H Harris; Nancy A Hessol Journal: AIDS Date: 2011-02-20 Impact factor: 4.177
Authors: B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti Journal: JAMA Date: 1999-12-15 Impact factor: 56.272
Authors: Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Anuradha Ganesan; Amy Weintrob; Jason F Okulicz; Brian K Agan Journal: AIDS Date: 2010-11-27 Impact factor: 4.177
Authors: Elizabeth K Cahoon; Eric A Engels; D Michal Freedman; Mary Norval; Ruth M Pfeiffer Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger Journal: Int J Cancer Date: 2014-05-02 Impact factor: 7.396
Authors: Anna E Coghill; Polly A Newcomb; Margaret M Madeleine; Barbra A Richardson; Innocent Mutyaba; Fred Okuku; Warren Phipps; Henry Wabinga; Jackson Orem; Corey Casper Journal: AIDS Date: 2013-11-28 Impact factor: 4.177
Authors: Susan E Krown; Carlee B Moser; Patrick MacPhail; Roy M Matining; Catherine Godfrey; Stephanie R Caruso; Mina C Hosseinipour; Wadzanai Samaneka; Mulinda Nyirenda; Naftali W Busakhala; Fred M Okuku; Josphat Kosgei; Brenda Hoagland; Noluthando Mwelase; Vincent O Oliver; Henriette Burger; Rosie Mngqibisa; Mostafa Nokta; Thomas B Campbell; Margaret Z Borok Journal: Lancet Date: 2020-03-05 Impact factor: 79.321